...
首页> 外文期刊>Antibodies >Molecular Engineering of Therapeutic Cytokines
【24h】

Molecular Engineering of Therapeutic Cytokines

机译:治疗性细胞因子的分子工程

获取原文
           

摘要

Over the past three decades, a large body of work has been directed at the development of therapeutic cytokines. Despite their central role in immune modulation, only a handful of cytokine therapeutics has achieved regulatory approval. One of the major challenges associated with the therapeutic use of cytokines relates to their short serum half-life and low bioavailability. High doses are required to overcome these problems, which often result in dose-limiting toxicities. Consequently, most cytokines require protein engineering approaches to reduce toxicity and increase half-life. For this purpose, PEGylation, fusion proteins, antibody complexes and mutagenesis have been utilized. Here, we summarize past, recent and emerging strategies in this area.
机译:在过去的三十年中,大量工作致力于治疗性细胞因子的开发。尽管它们在免疫调节中起着核心作用,但只有少数几种细胞因子疗法获得了监管部门的批准。与细胞因子的治疗用途相关的主要挑战之一是它们的血清半衰期短和生物利用度低。需要高剂量来克服这些问题,这些问题通常会导致剂量限制的毒性。因此,大多数细胞因子需要蛋白质工程方法来减少毒性并增加半衰期。为了这个目的,已经使用了PEG化,融合蛋白,抗体复合物和诱变。在这里,我们总结了该领域过去,最近和新兴的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号